Testing Minimal Residual Disease in NonSecretory Myeloma Patients with clonoSEQ
Meet with us this month to discuss minimal residual disease testing and how it can be beneficial to nonsecretory myeloma patient care.
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Vicki Jones
In the 20 years since her diagnosis Vicki has learned a lot about fighting myeloma. In her own words, "When I was diagnosed it felt like I was the only one in the world with this disease. After always having been a bit of a loner, suddenly I yearned for someone to talk to that understood what I was going through. Now I want to be that someone for other myeloma patients and caregivers". Vicki has been on just about every chemo regimen and has had a stem cell transplant. Every drug regimen has worked against her Myeloma but she has never been in complete remission. She recently became a nonsecretor and is learning to deal with this new diagnosis. "When I was diagnosed in 2004 it made me sad to think I would never know what it was like to grow old. Now when I look in the mirror and see all the wrinkles, I’m overjoyed!"
Mark Schliekelman
Experienced Medical Science Liaison with with deep understanding of Oncology and Pharmaceuticals . Skilled in Scientific Review, Molecular Biology, Biotechnology, Cell Culture, and Scientific Writing. Strong research professional with a Doctor of Philosophy (Ph.D.) focused in Genetics and Molecular Biology from UNC Chapel Hill. I see my role: As identifying engaging and maintaining relationships with Key Opinion Leaders. To be a collaborative and supportive partner with business and research professionals. As a Medical Affairs Facilitator and subject matter expert with a demonstrated ability effectively communicate. To provide information that is clear, concise and clinically relevant. To ask provocative questions that challenge current assumptions. Provide thoughtful answers to queries and concerns. Give peer level support in ensuring well-run research and trials. I consider myself to be a person of integrity; principled, diplomatic, calm, thoughtful and reflective. I have a deep understanding of oncology and am able to go toe to toe with Key Opinion Leaders in an engaging scientific exchange.